Share Name Share Symbol Market Type Share ISIN Share Description
Sensyne Health Plc LSE:SENS London Ordinary Share GB00BYV3J755 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -1.55% 158.50 237,878 14:48:07
Bid Price Offer Price High Price Low Price Open Price
155.00 162.00 160.00 154.50 160.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.14 -18.99 -19.00 252
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:10 O 25,000 158.50 GBX

Sensyne Health (SENS) Latest News

More Sensyne Health News
Sensyne Health Investors    Sensyne Health Takeover Rumours

Sensyne Health (SENS) Discussions and Chat

Sensyne Health Forums and Chat

Date Time Title Posts
10/4/202110:19Sensyne Health - Clinical AI452
27/11/201912:04Sensyne Health PLC83

Add a New Thread

Sensyne Health (SENS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-14 16:06:11158.5025,00039,625.00O
2021-04-14 14:58:11160.009001,440.00O
2021-04-14 13:48:40160.001,2632,020.80O
2021-04-14 13:48:05160.002,0003,200.00O
2021-04-14 13:47:18160.003,9266,281.60O
View all Sensyne Health trades in real-time

Sensyne Health (SENS) Top Chat Posts

Sensyne Health Daily Update: Sensyne Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SENS. The last closing price for Sensyne Health was 161p.
Sensyne Health Plc has a 4 week average price of 154.50p and a 12 week average price of 140p.
The 1 year high share price is 191p while the 1 year low share price is currently 26.50p.
There are currently 159,084,855 shares in issue and the average daily traded volume is 74,838 shares. The market capitalisation of Sensyne Health Plc is £252,149,495.18.
billy3: Well it’s gone a little quiet recently but the share price seems steady. Sens seems to release a lot of news on a Friday so we are overdue something. As I’ve mentioned before, the LFT deal with Excalibur could be huge and not priced in. As expected, the government has now confirmed that LFTs are a big part of the way ahead. I was surprised at exactly how big and how many tests will be available. We haven’t seen the results if the pilot yet which includes Sens and they have been paid half a million for. Excalibur can produce 3 million tests per day. If Uk population can be able to test up to twice per week and even get 7 kits at a time at a pharmacist, I see no reason why they can’t shift 3 million a day. So, that’s 21 million tests per week. Even if Sens received 10p per test carried out, that’s a whopping £2.1 million per week !!! I guess we will have to wait for the next report. The positive is that Sens is not a ‘one trick pony’ and this deal is just one element of what they already have and in the pipeline. If Excalibur confirms they will be shipping at Capacity and each kit is linked to the Sens app (which no other her company has where tests can be read and recorded by a smartphone) then Sens would be on a potential PE of less than 2 ! All based on rough figures of course. Discuss :-)
billy3: Edwart I’ve also read up on the use of synthetic control arms. It’s a really interesting concept, using historical patient data as the placebo group. Two main benefits I see. Firstly to the placebo patients as it means that a patient who may have cancer (for example) is guaranteed to get the trialled drug as the control group is basically AI. The second is cost. An example given if 1000 people for a trial is reduced by half. So the cost is also halved. For the big pharmaceutical companies this will save a huge amount of money and speed up trials. Where do Sens come in to it ? Well Phesi have been working on this for some time. But adding their data to sens gives over 36 million patient data sets. The Pharmas, so far as I know, don’t have this data. So using AI plus data plus Phesi knowledge and research has huge potential IMO. I can see one of the big companies wanting to buy Sens in the future. Having this AI and data must be hugely advantageous. And the current value of sens is peanuts to them. Another advantage I forget is that the pandemic has highlighted the difficulty of getting large groups for trials. They have almost stopped during the pandemic so there is pent up demand. With regards to’;s been tempting to sell some. But I’m in for the ups and downs for now. I’m not so sure that results will show much profit. But.....if you look at what has been announced, there is significant potential in the pipeline for revenue. The above I’ve mentioned is the first. The move in to the US should also bring in revenue. Previous brokers targets were £2.60-70 I believe. Another piece says 300-400 in 3 to 4 years. I known just hearing about deals and potential isn’t adding to the bottom line, but once the tap opens, I see the revenue coming in and the share price accelerating. Having the balls to hold on is the hard bit see it drop form 1500 back down to 110p. But yet again, we are almost back up there again. I just hope we don’t drop back again on or after results. That said, yesterday saw some rather large buys coming in. Even with the share issue, it looks like someone one is building a position.
billy3: Sensyne Health PLC 13 November 2020 Sensyne Health appoints President, North America, to lead US expansion Oxford, U.K. 13 November 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company's North American operations, building Sensyne's presence in the US and recruiting a US-based team. Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner. Derek is a US national and will be based in the US. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "I'm delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business." Derek Baird, said: "I've been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I'm excited to bring the Sensyne vision and unique business model to the US market."
rambutan2: I suppose what is interesting is how much of a seller Acacia is. I think the mkt had assumed they would dump big time almost regardless of price, as they had with other Link stuff they'd got hold of. Hence the horribly low share price for much of the year. However, if, as looks the case so far, they are sitting tight or just selling down v slowly, then there are few loose shares around to supply demand as the good news flows. Clifford Press, CEO of Acacia Research , commented: " We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth." Might pick up some info a week mon: Acacia Research Corporation (“Acacia” or “the Company”) (NASDAQ: ACTG) announced today it will release its third quarter financial results on Monday, November 9, 2020 at 8:00 a.m. ET/ 5:00 a.m. PT. The Company will host a conference call on the same day to discuss these results at 11:00 a.m. ET/ 8:00 a.m. PT. To access the live call, please dial (877) 407-0778 (U.S. and Canada) or (201) 689-8565 (international). The conference call will also be simultaneously webcasted on the investor relations section of the Company’s website at hTtp:// under the News & Events tab. Following the conclusion of the live call, a replay of the webcast will be available on the Company's website for at least 30 days.
billy3: Another agreement today RNS Number : 8455A Sensyne Health PLC 01 October 2020 Sensyne Health and NHS Greater Glasgow and Clyde sign data access agreement Oxford, U.K. 1 October 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces it has signed a non-exclusive data sharing agreement with NHS Greater Glasgow and Clyde ("NHSGGC") giving Sensyne access to three separate anonymised patient data sets in three specific disease areas including cardiovascular disease. The anonymised patient data will be used by Sensyne to undertake medical research using Clinical AI, improve pharmaceutical development and help deliver better patient care. NHSGGC is one of 14 regional NHS Boards in Scotland. It serves a population of 1.14 million and employs around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK including 35 Hospitals of different types. The agreement falls under the Glasgow Safe Haven partnership between NHS Greater Glasgow and Clyde and the University of Glasgow, designed to provide secure access to NHS and other health datasets derived from diverse sources across the health service. The Glasgow Safe Haven is accredited by the Scottish Government as an accredited Safe Haven, and is one of four regional Safe Havens across Scotland. By enabling researchers to link data from different sources, Safe Havens encourage data-driven health research to improve health services, design better treatments, and to create innovative new health products to support better health in Scotland. Prof Julie Brittenden, Director of Research and Innovation, NHS Greater Glasgow and Clyde, said: "We are pleased to collaborate with Sensyne on data-driven approaches which aim to ultimately improve early diagnosis and treatment of various illnesses, including cardiovascular disease. The project will use anonymised patient data within the secure Glasgow Safehaven to test Sensyne's machine learning models. This is one of many of our collaborations with industry to improve research and development in order to benefit our patients in future." Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "We are delighted to be working with one of the largest NHS Boards in Scotland on data analysis to improve patient care and accelerate medical research. Adding this data sharing agreement to our Strategic Research Agreements expands our access to anonymised patient data to now cover 3.9 million patients." -ENDS-
billy3: RNS Number : 6245A Sensyne Health PLC 30 September 2020 Sensyne Health announces collaboration with the University of Oxford to provide software for remote symptom data collection and analytics for a Phase II clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19 Highlights : · Sensyne's software for remote symptom data collection and analytics will support researchers in academia and the pharmaceutical industry to undertake clinical trials during the pandemic, particularly within the community environment · Collaboration with the University of Oxford for the AVID-CC Phase II clinical trial in care homes of the anti-TNF drug adalimumab funded by the Wellcome Trust · Further agreements to use Sensyne's capabilities in other clinical trials are in advanced discussions Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces a collaboration with the University of Oxford in which Sensyne will provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19. The trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from an array of public and philanthropic donors. The purpose of the trial is to assess the effectiveness of Adalimumab in preventing progression to respiratory failure or death due to COVID-19 infection. A particular feature of this trial, supported by Sensyne's software, is the remote collection of data on symptoms, vital signs and activities of daily living from clinical trial subjects in care homes, followed by a phase of exploratory data analysis using Sensyne's machine learning algorithms. The software is based on Sensyne's CVm-Health ™ software application for tracking COVID-19 symptoms launched earlier this year. The use of CVm-Health will allow clinical trial participants in care homes to record their symptoms and vital signs and enable trial investigators to access such data remotely. The 'Good Neighbour' aspect of CVm-Health, whereby a carer, with consent, can enter data on behalf of an individual, is an important feature that facilitates clinical trials in the community care environment. Under the trial protocol, and with the consent of participants, anonymised data recorded by the application during the trial will be analysed using machine learning algorithms developed by Sensyne. Sensyne is in advanced discussions for the use of its remote symptom and vital sign data collection software and analytics expertise by other clinical researchers seeking to undertake drug trials during the COVID-19 pandemic, particularly trials within community settings such as care homes. Further announcements will be made as such discussions reach agreement. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic. We are delighted to be working with the University of Oxford on this important new trial of Adalimumab , pioneering new clinical research techniques in the community environment." Professor Duncan Richards FRCP, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU), formerly Head of Clinical Pharmacology and Experimental Medicine for GSK (until 2019), who is the Chief Investigator for the AVID-CC trial , said: " We have been impressed by Sensyne Health's digital health and clinical AI capabilities. We are excited by the opportunity that that flexible electronic diaries for remote data collection and analytics, such as CVm-Health for patients and carers to contribute to information collected in clinical trials. This pandemic has highlighted the need to re-examine the ways in which we collect data. We are delighted to be working with Sensyne and are excited by the potential for unique insights that may come from exploratory analyses of the anonymised clinical trial data using their proprietary machine learning algorithms." -ENDS-
rambutan2: At last! Oxford, U.K. 29 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, notes that on 5 June 2020, Acacia Research Corporation (Nasdaq: ACTG) announced that it had entered into an agreement with Link Fund Solutions Limited ("LFS") to purchase shares in a number of public and private life sciences companies from the LF Equity Income Fund which was previously managed by Woodford Investment Management Limited. The agreement was structured to take ownership of portfolio positions in a staged manner. Sensyne Health welcomes Acacia Research as an 11.8% shareholder and the clarity brought to the market with this announcement for the previously anticipated share transfer. Clifford Press, CEO of Acacia Research , commented: " We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth."
rambutan2: A BIG tick: Oxford, U.K. 10 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020. Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems. Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister's Delivery Unit. Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne's unique business model and ethical approach to the use of clinical AI." Michael Macdonnell, said: "Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world." htTps://
mrc2u: >>gilesyDisagree that most CEOs would have been sacked because of SENS share price performance. They raised a stack of cash at IPO to pursue a plan and are getting on with it. They claim up front to have hit all the 24 month objectives from IPO early. No reason to fire a CEO for setting out a plan, getting it funded and then delivering against it. The bonus shambles is the only reason so far to fire Drayson and he has at least tried to deploy some fig leaves on thatSENS shares down from 175p to 50p giving a market cap of around GBP60m. Worth looking at private company Benevolent AI, where Woodford also had a big stake. Its value on latest raise was halved from USD2bn to USD1bn. Latest results show revenue of GBP6m and cash consumed if GBP50m. If SENS does get revenues north of GBP2m, which looks likely, and burns about 15m it ought to be worth more than one twelfth of Benevolent after a huge crash in Benevolent's valie. It would also still have 18 months to two years cash left with any additional revenues extending the runwayYes it's hard to value this. You have merely shown that it is easy to troll itMrC
Sensyne Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Sensyne He..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 03:07:20